Indeed, under cisplatin treatment, CAFs promote the phosphorylation and activation of STAT3, which upregulates the levels of BCL-2 in ovarian cancer [32] and in lung adenocarcinoma triggered by IL11 paracrine signaling [33], thus resulting in chemoresistance. This evidence concerns the gene STAT3 and ovarian carcinoma.